Skip to main contentAll experts

Jianping Huang

RES PROF

MD-NEUROLOGICAL SURGERY

Orcid identifier0000-0001-7442-2669 (opens in a new tab)⁠
  • RES PROF
    MD-NEUROLOGICAL SURGERY

GRANTS

  • GRANT
    Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapy
    National Institute of Health Nci17 Jul 2026 - 31 Jul 2029
    Active
  • GRANT
    Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic
    National Institute of Health Nci13 Mar 2026 - 31 Aug 2026
    Active
  • GRANT
    Metabolic interactions between tumor cells and the immune system in GBM A potential Achilles heel of GBM for novel therapeutics
    National Institute of Health Ninds29 Aug 2025 - 31 Jul 2027
    Active
  • GRANT
    Enhance Cancer Therapeutics with 3-in-1 CAR T Cells
    National Institute of Health Nci13 Aug 2025 - 30 Jun 2027
    Active
  • GRANT
    Enhancing antitumor efficacy by intratumoral delivering LAIR1 inhibitory signaling
    National Institute of Health Nci5 Aug 2025 - 31 Jul 2027
    Active
  • GRANT
    Phase I clinical trial for pediatric high-grade glioma using 8R-70CAR T cells
    St Baldricks Foundation31 Jul 2025 - 30 Jun 2027
    Active
  • GRANT
    Advancing cancer therapy: Developing antibody blockade targeting a novel immune checkpoint, LAIR1/CD305
    National Institute of Health Nci28 Jul 2025 - 31 May 2027
    Active
  • GRANT
    Clinical Evaluation of First-In-Human Trial for Glioblastoma with 8R-70CAR T Cells: ABTA Jack & Fay Netchin Medical Student Summer Fellowship for Gopi Patel
    American Brain Tumor Association14 Jul 2025 - 13 Oct 2025
    Expired
  • GRANT
    Metabolic engineering of CD70CAR T cells to enhance immunotherapy targeting DIPG
    20 Sep 2024 - 2 Nov 2024
    Expired
  • GRANT
    Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapy
    National Institute of Health Nci12 Aug 2024 - 31 Jul 2026
    Expired
  • GRANT
    Optimizing CAR T therapy via metabolic engineering for the treatment of GBM
    5 Jul 2023 - 25 Oct 2024
    Expired
  • GRANT
    Phase I/II clinical trial for malignant pediatric gliomas using 8R-70CAR T cells
    Florida Department of Health Live Like Bella26 May 2023 - 31 Mar 2027
    Active
  • GRANT
    Adoptive Cellular Therapy Targeting Recurrent/Progressive Oligodendroglioma
    Oligo Nation29 Mar 2023 - 28 Feb 2027
    Active
  • GRANT
    Metabolic interactions between tumor cells and the immunce system in GBM A potential Achilles heel of GBM for novel therapeutics
    28 Jul 2022 - 31 Jul 2025
    Expired
  • GRANT
    Leveraging CD70 CXCR2-modified CAR T-cells for treating AML
    Society for Immunotherapy of Cancer1 Jul 2022 - 31 Jan 2024
    Expired
  • GRANT
    SPDYE3, A Novel Cancer Testis (CT) Antigen for Glioma Immunotherapy
    National Institute of Health Nci21 Apr 2022 - 31 Mar 2024
    Expired
  • GRANT
    Unlocking CAR T cell efficacy against osteosarcoma using adjuvant RNA vaccine
    Florida Department of Health Live Like Bella29 Mar 2022 - 31 Mar 2025
    Expired
  • GRANT
    Co-opting TME lactate signal to benefit T cell therapy
    Florida Department of Health Live Like Bella1 Feb 2022 - 31 Mar 2025
    Expired
  • GRANT
    Targeting Oligodendrogliomas with LAIR1/CD305 Blockade
    Oligo Nation13 Aug 2021 - 31 Oct 2023
    Expired
  • GRANT
    Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
    National Institute of Health Nci25 Jan 2021 - 31 Jan 2026
    Expired
  • GRANT
    Clinical Development of CAR T Cell Therapy Targeting CD70 in Primary Glioblastoma
    US Army Med Research Acquisition1 Sep 2020 - 31 Aug 2023
    Expired
  • GRANT
    Clinical Development of CAR T Cell Therapy Targeting CD70 in Primary Glioblastoma
    Congressionally Directed Medical Research Programs1 Sep 2020 - 31 Aug 2023
    People funded by this grant:
    • HUANG J
  • GRANT
    Targeting glioma slow-cycling cells using autologous dendritic cell vaccine
    13 Jun 2018 - 30 Sep 2019
    Expired
  • GRANT
    MBE2S affects the molecular mechanism of GBM resistance to TMZ through endoplasmic reticulum stress protein GRP78 (opens in a new tab)⁠
    National Natural Science Foundation of China1 Jan 2018 - 31 Dec 2021
    People funded by this grant:
    • Lin Z,
    • Hu L,
    • Huang J,
    • Laura A,
    • Yin Y
    MORELEARN MORE (opens in a new tab)
  • GRANT
    A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-PD-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs
    National Institute of Health Nci13 May 2016 - 30 Sep 2026
    Active